Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356991 | 0.88 | SCN9A (0.49) | SCN9ATACR3SLC6A9KMT2ALMNA | |
| SCHEMBL4356096 | 0.88 | KDM4E (0.41) | CXCR5SCN9ATACR3SLC6A9 | |
| SCHEMBL4359374 | 0.87 | SLC6A9 (0.41) | SCN9ATACR3SLC6A9MEN1KMT2A | |
| SCHEMBL3240639 | 0.87 | SLC6A9 (0.38) | SLC6A9MEN1KMT2ALMNAHPGD | |
| SCHEMBL4357362 | 0.85 | PLK1 (0.50) | SCN9ATACR3SLC6A9MEN1KMT2A | |
| SCHEMBL4358082 | 0.84 | SLC22A12 (0.40) | SCN9AMAPK10TACR3SLC6A9LMNA | |
| SCHEMBL3238085 | 0.83 | TAS1R3 (0.41) | SLC6A9MEN1KMT2A | |
| SCHEMBL3239804 | 0.82 | SLC6A9 (0.47) | SLC6A9MEN1KMT2A | |
| SCHEMBL4361757 | 0.81 | NCEH1 (0.40) | TACR3SLC6A9MEN1KMT2ALMNA | |
| SCHEMBL4352703 | 0.81 | PREP (0.49) | TACR3SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2006067430-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | PNMT, SLC18A2, COMT | CXCR5 4405/4885SCN9A 3102/4885MAPK10 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.